Adjunctive Use of Polynucleotide and Hyaluronic Acid-based Gel in Alveolar Preservation After Tooth Extraction

Launched by ADRIÀ JORBA GARCÍA · Oct 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to help preserve the bone in your jaw after a tooth is extracted. When a tooth is removed, the bone around it can shrink over time, which can make it harder to place a dental implant later. The trial will test a special gel made from polynucleotides and hyaluronic acid, which may help keep the bone healthy and support its growth after tooth extraction. Researchers want to see how effective this gel is in promoting better healing in the jaw.

To participate in this trial, you need to be an adult over 18 years old who requires the removal of a single non-molar tooth, like a premolar or canine, and plans to get a dental implant afterward. Certain health conditions and medications may prevent you from joining, such as having an active infection or being pregnant. If you join the study, you can expect to receive the gel treatment during your tooth extraction procedure, and you will be monitored to see how well it works in preserving your jawbone. This trial is not yet recruiting participants, but it aims to provide valuable information for future dental care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (\>18 years) who need the extraction of a single non-molar tooth in the mandible or maxilla.
• • ASA I or II
• • Intact post-extraction socket or with only one wall dehiscence (buccal or lingual) of no more than 50% of the socket.
• • The treatment plan must include the replacement of the tooth to be extracted by placing an implant and an implant-supported prosthesis.
• Exclusion Criteria:
• • Mandibular incisors and molars.
• • Acute infection associated with the tooth that needs to be extracted.
• • Uncontrolled systemic disease.
• • Pregnant patient.
• • Patient under treatment with antiresorptives drugs (bisphosphonates or Receptor Activator of Nuclear Factor Kappa-B Ligand (i.e., Denosumab)) or antiangiogenics.
• • Smokers (\>10 cigarettes a day).